Personalized Management of Bone and Mineral Disorders and Precision Medicine in End-Stage Kidney Disease.

ABSTRACT: Chronic kidney disease mineral bone disorder (CKD-MBD) is common in end-stage renal disease and is associated with an increased risk of cardiovascular morbidity and mortality. Mainstays of treatment include decreasing serum phosphorus level toward the normal range with dietary interventions and phosphate binders and treating increased parathyroid hormone levels with activated vitamin D and/or calcimimetics. There is significant variation in serum levels of mineral metabolism markers, intestinal absorption of phosphorus, and therapeutic response among individual patients and subgroups of patients with end-stage renal disease. This variation may be partly explained by polymorphisms in genes associated with calcium and phosphorus homeostasis such as the calcium-sensing receptor gene, the vita

SUBMITTER: Jovanovich A 

PROVIDER: S-EPMC6615060 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature